FMP
Oppenheimer Raised its Price Target on Prothena Corporation to $100 from $90
Sep 27, 2021(Last modified: Dec 19, 2023)
Analysts at Oppenheimer increased their price target on Prothena Corporation plc (NASDAQ:PRTA) to $100 from $90, as they refresh their favorable outlook on the company due to the recent update of FDA's Surrogate Endpoint Table, which now includes a reduction in amyloid-ß plaque for mAbs in mild-AD patients as appropriate for accelerated approval.
The analysts see confirmation that the company should benefit from regulatory precedence plus BIIB's launch efforts, noting that BIIB's Aduhelm was approved based on this surrogate endpoint.
MicroStrategy Incorporated (NASDAQ:MSTR) Earnings Preview and Bitcoin Investment Strategy
MicroStrategy Incorporated (NASDAQ:MSTR) is a prominent business intelligence company known for its software solutions a...
WACC vs ROIC: Evaluating Capital Efficiency and Value Creation
Introduction In corporate finance, assessing how effectively a company utilizes its capital is crucial. Two key metri...
BofA Sees AI Capex Boom in 2025, Backs Nvidia and Broadcom
Bank of America analysts reiterated a bullish outlook on data center and artificial intelligence capital expenditures fo...
